KMT2D and cancer: KRAS, LRP1B, and TP53 (bortezomib-insensitive cell lines) and CREBBP, KMT2C, KMT2D, and TP53 (bortezomib-sensitive cell lines) were identified as commonly mutated cancer drivers in ≥ 5 cell lines (Supplementary Fig. 2a-b).